Trial Profile
Analysis of efficacy of the SGLT2 inhibitor alone or in combination with the DPP-4 inhibitor on urinary and plasma DPP-4 activities in obese patients with type 2 diabetes.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Apr 2018
Price :
$35
*
At a glance
- Drugs Canagliflozin (Primary) ; Teneligliptin
- Indications Obesity; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 23 Apr 2018 Status changed from recruiting to completed.
- 18 Apr 2017 Status changed from not yet recruiting to recruiting.
- 08 Oct 2015 New trial record